HC Wainwright Issues Optimistic Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.69). HC Wainwright has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($2.39) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $2.15 EPS.

A number of other equities analysts also recently issued reports on the stock. B. Riley reaffirmed a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Bank of America lowered their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their price objective on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Trading Down 2.1%

NASDAQ DNLI traded down $0.30 during mid-day trading on Monday, hitting $13.96. The company's stock had a trading volume of 1,170,551 shares, compared to its average volume of 1,095,969. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -5.06 and a beta of 1.49. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $33.33. The company's 50 day simple moving average is $14.20 and its 200 day simple moving average is $19.87.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the business posted ($0.68) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DNLI. Sterling Capital Management LLC raised its position in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after acquiring an additional 1,551 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Denali Therapeutics during the first quarter valued at $41,000. GF Fund Management CO. LTD. purchased a new position in Denali Therapeutics during the fourth quarter valued at $62,000. Finally, Point72 Hong Kong Ltd purchased a new position in Denali Therapeutics during the fourth quarter valued at $65,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.